Amgen partners with Provention Bio on celiac disease treatment

You are here: Home > Biotech > Current Article

Amgen partners with Provention Bio on celiac disease treatment

By Staff Report / Monday, November 5th, 2018 / Comments Off on Amgen partners with Provention Bio on celiac disease treatment

Thousand Oaks biotech giant Amgen set its sights on the digestive autoimmune disorder known as celiac disease with a $20 million licensing and co-development deal with New Jersey-based Provention Bio. Announced Nov. 5, the partnership will develop an antibody to treat celiac disease that is not responsive to a gluten-free diet, or NRCD. Provention will…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.